# Macular Edema Incidence/Severity Reduction With Nevanac

> **NCT00939276** · PHASE3 · TERMINATED · sponsor: **Alcon Research** · enrollment: 175 (actual)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)
- **DRUG:** Nepafenac ophthalmic suspension vehicle

## Key facts

- **NCT ID:** NCT00939276
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08
- **Primary completion:** 2011-05
- **Final completion:** 2011-08
- **Target enrollment:** 175 (ACTUAL)
- **Why stopped:** Patient recruitment difficulties
- **Last updated:** 2012-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00939276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00939276, "Macular Edema Incidence/Severity Reduction With Nevanac". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00939276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*